Departmental Papers (Dental)

Document Type

Journal Article

Date of this Version


Publication Source

Oral Diseases





Start Page


Last Page





Ameloblastoma is a benign odontogenic tumor of epithelial origin. It is locally aggressive with unlimited growth capacity and has a high potential for malignant transformation as well as metastasis. Ameloblastoma has no established preventive measures although majority of patients are between ages 30 and 60 years. Molecular and genetic factors that promote oncogenic transformation of odontogenic epithelium to ameloblastoma are strongly linked to dysregulation of multiple genes associated with mitogen-activated protein kinase, sonic hedgehog, and WNT/β-catenin signaling pathways. Treatment of ameloblastoma is focused on surgical resection with a wide margin of normal tissue because of its high propensity for locoregional invasion; but this is often associated with significant patient morbidity. The relatively high recurrence rate of ameloblastoma is influenced by the type of molecular etiological factors, the management approach, and how early the patient presents for treatment. It is expected that further elucidation of molecular factors that orchestrate pathogenesis and recurrence of ameloblastoma will lead to new diagnostic markers and targeted drug therapies for ameloblastoma. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Copyright/Permission Statement

This is the peer reviewed version of the following article: [Effiom, O., Ogundana, O., Akinshipo, A., & Akintoye, S. (2018). Ameloblastoma: Current etiopathological concepts and management. Oral Diseases, 24(3), 307-316.], which has been published in final form at []. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving [link to].


ameloblastoma; etiopathogenesis; histopathogenesis; jaw; targeted therapies

Included in

Dentistry Commons



Date Posted: 10 February 2023

This document has been peer reviewed.